Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Cancer Research and Treatment. 2023;55(1):344-349 
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69
P76.87 Efficacy of Dacomitinib in EGFR TKI Refractory Metastatic Non-Small Cell Lung Cancer (EGFR Mutant) with Leptomeningeal Metastases
Journal of Thoracic Oncology. 2021;16(3):S627
Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment
. 2019;
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Annals of Oncology. 2020;31(10):1397-1404
A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L)
Clinical Lung Cancer. 2021;22(4):376-380
Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
British Journal of Cancer. 2017;118(1):32-37
P1.01-100 Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy
Journal of Thoracic Oncology. 2019;14(10):S400
Reversal of Acquired Resistance to EGFR–TKI in T790M-negative Patients With Non–small-cell Lung Cancer Using Anlotinib
. 2021;
Osimertinib plus Bevacizumab Improve the Outcome of Leptomeningeal Metastasis Patients with EGFR Mutant Non-Small-Cell Lung Cancer
. 2022;